Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2011 07:00 ET | Source: Intellect Neurosciences, Inc.

Michael Grundman, MD, MPH, Alzheimer's Disease Clinical Trials Expert, Joins Intellect Neurosciences' Clinical Advisory Board

NEW YORK, May 16, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
April 12, 2011 06:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Files Orphan Drug Application in the United States for Its Clinical Candidate OX1 for the Treatment of Friedreich's Ataxia

NEW YORK, April 12, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
April 08, 2011 14:05 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Initiates Capital Markets Plan

NEW YORK, April 8, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
April 05, 2011 06:00 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Receives New Patent on Clinical Stage Drug from the Israeli Patent and Trademark Office

NEW YORK, April 5, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
March 10, 2011 09:57 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Chairman & CEO Dr. Daniel G. Chain Recognized as Individual of "Extraordinary Abilities" in Alzheimer's Drug Research by the United States Government

NEW YORK, March 10, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
March 08, 2011 10:43 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Obtains New Patent for Alzheimer's Vaccine From the United States Patent and Trademark Office ("USPTO")

NEW YORK, March 8, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
February 22, 2011 14:15 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Issues Shareholder Update

NEW YORK, Feb. 22, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
December 27, 2010 09:21 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. Obtains Pharmacokinetic Profile Report From Fourteen Day Safety Trial for the Company's Lead Alzheimer's Candidate, OX1

NEW YORK, Dec. 27, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with...
December 08, 2010 07:30 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences CEO to be "Distinguished Speaker" at Center for Business Intelligence 4th Annual Alzheimer's Drug Development Summit

NEW YORK, Dec. 8, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline, and multiple licenses with...
November 22, 2010 07:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Issues Shareholder Update

NEW YORK, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...